Database : MEDLINE
Search on : Amphetamine-Related and Disorders [Words]
References found : 2613 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 262 go to page                         

  1 / 2613 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29465560
[Au] Autor:Xue X; Song Y; Yu X; Fan Q; Tang J; Chen X
[Ad] Address:Department of Substance Abuse, Qingdao Mental Health Center, Qingdao.
[Ti] Title:Olanzapine and haloperidol for the treatment of acute symptoms of mental disorders induced by amphetamine-type stimulants: A randomized controlled trial.
[So] Source:Medicine (Baltimore);97(8):e9786, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: This study aimed to compare olanzapine and haloperidol efficacies in the treatment of acute psychiatric symptoms due to amphetamine-type stimulants (ATSs). METHODS: The Zelen II design method was used; 124 patients with acute mental disorders due to amphetamine were randomly divided into olanzapine group (n = 63) and haloperidol group (n = 61). Then, a 4-week open-label medical therapy was performed. Clinical Global Impression Scale Item 2 was employed to evaluate the onset time; meanwhile, Brief Psychiatric Rating Scale (BPRS) was used at baseline and at posttreatment weeks 1, 2, and 4. Moreover, adverse reactions during the treatment were recorded. RESULTS: Onset time in the olanzapine group was significantly earlier than in the haloperidol group; BPRS scores in the olanzapine group were significantly lower than haloperidol group values at 1 and 2 weeks of treatment. The overall effective rates had no statistically significant difference. CONCLUSION: Short-term olanzapine and haloperidol treatments had equivalent efficacies in the treatment of acute symptoms of mental disorders due to ATSs; however, olanzapine administration resulted in relatively earlier disease onset, with less adverse reactions.
[Mh] MeSH terms primary: Amphetamine-Related Disorders/drug therapy
Antipsychotic Agents/administration & dosage
Benzodiazepines/administration & dosage
Haloperidol/administration & dosage
Mental Disorders/drug therapy
[Mh] MeSH terms secundary: Adult
Amphetamine/adverse effects
Amphetamine-Related Disorders/psychology
Brief Psychiatric Rating Scale
Central Nervous System Stimulants/adverse effects
Female
Humans
Male
Mental Disorders/chemically induced
Research Design
Treatment Outcome
[Pt] Publication type:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Name of substance:0 (Antipsychotic Agents); 0 (Central Nervous System Stimulants); 12794-10-4 (Benzodiazepines); CK833KGX7E (Amphetamine); J6292F8L3D (Haloperidol); N7U69T4SZR (olanzapine)
[Em] Entry month:1803
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009786

  2 / 2613 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27776672
[Au] Autor:Hellem TL
[Ad] Address:Montana State University College of Nursing, Missoula, MT 59812-7416, United States. Electronic address: tracy.hellem1@montana.edu.
[Ti] Title:A Review of Methamphetamine Dependence and Withdrawal Treatment: A Focus on Anxiety Outcomes.
[So] Source:J Subst Abuse Treat;71:16-22, 2016 12.
[Is] ISSN:1873-6483
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Rates of anxiety disorders among individuals who use methamphetamine are estimated to be as high as 30.2%. The presence of an anxiety disorder in methamphetamine users is associated with higher rates of relapse, non-adherence to treatment and poorer outcomes relative to methamphetamine users without an anxiety disorder. A review investigating current treatment options for methamphetamine dependence or withdrawal from methamphetamine was conducted using PubMed, CINAHL and PsycINFO. The focus of the review was trials that utilized an intervention and collected anxiety as an outcome measure. Seven studies were included in the review, and five of these studies examined a pharmacotherapy option, one studied a psychosocial intervention and one study investigated exercise as an intervention. Some of the pharmacotherapy studies and the study of exercise were associated with improvements in mood and/or a reduction in methamphetamine use. Concerns of sample size and measurement of anxiety were raised. Future well-designed research with large sample sizes is warranted to examine how to manage anxiety among methamphetamine users.
[Mh] MeSH terms primary: Amphetamine-Related Disorders/therapy
Anxiety Disorders
Central Nervous System Stimulants
Methamphetamine
Outcome Assessment (Health Care)
Substance Withdrawal Syndrome/therapy
[Mh] MeSH terms secundary: Humans
[Pt] Publication type:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Central Nervous System Stimulants); 44RAL3456C (Methamphetamine)
[Em] Entry month:1712
[Cu] Class update date: 180215
[Lr] Last revision date:180215
[Js] Journal subset:IM
[Da] Date of entry for processing:161026
[St] Status:MEDLINE

  3 / 2613 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28448903
[Au] Autor:Argento E; Strathdee SA; Goldenberg S; Braschel M; Montaner J; Shannon K
[Ad] Address:Gender and Sexual Health Initiative, BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada; Interdisciplinary Studies Graduate Program, University of British Columbia, 2357 Main Mall, Vancouver, BC, V6T 1Z4, Canada.
[Ti] Title:Violence, trauma and living with HIV: Longitudinal predictors of initiating crystal methamphetamine injection among sex workers.
[So] Source:Drug Alcohol Depend;175:198-204, 2017 06 01.
[Is] ISSN:1879-0046
[Cp] Country of publication:Ireland
[La] Language:eng
[Ab] Abstract:BACKGROUND: Despite rapid increases in crystal methamphetamine (CM) use worldwide and established gendered patterns of use, empirical research on CM injection initiation among sex workers is limited. Given the wide range of harms associated with CM, alongside stimulant effects including sexual dis-inhibition and prolonged awake-ness, this study aimed to longitudinally investigate socio-structural predictors of initiating CM injection among sex workers in Vancouver, Canada. METHODS: Data (2010-2014) were drawn from a community-based cohort of women sex workers: AESHA (An Evaluation of Sex Workers Health Access). Participants completed bi-annual interviewer-administered questionnaires and HIV/STI testing. Kaplan Meier methods and Cox proportional hazards regression were used to model predictors of CM injection initiation among CM injection-nave participants. RESULTS: Of 455 participants eligible at baseline, 14.3% (n=65) injected CM for the first time over follow-up, with an incidence density of 6.79 per 100 person-years (95% Confidence Interval [CI] 5.30-8.69). In multivariable analysis, injection heroin use (Adjusted Hazard Ratio [AHR] 6.11; 95%CI 3.24-11.52), having an intimate partner who injects drugs (AHR 2.93; 95%CI 1.57-5.46), workplace violence (AHR 2.85; 95%CI 1.74-4.67), HIV seropositivity (AHR 2.69; 95%CI 1.45-5.00), and childhood abuse (AHR 1.86; 95%CI 0.99-3.49) were independently associated with initiating CM injection. CONCLUSIONS: Findings underscore the gendered and social risk environment of CM injection initiation among sex workers. The strong influences of historical/workplace violence, coupled with heroin injection (known to be self-medicating for post-traumatic stress) as a primary risk pathway, emphasize the urgency of increasing access to integrated, trauma-informed addiction treatment and HIV care for marginalized women.
[Mh] MeSH terms primary: Amphetamine-Related Disorders/psychology
HIV Infections/psychology
Sex Workers/psychology
Substance Abuse, Intravenous/psychology
Violence/psychology
[Mh] MeSH terms secundary: Adolescent
Adult
British Columbia
Cohort Studies
Female
Humans
Incidence
Injections/psychology
Longitudinal Studies
Methamphetamine/administration & dosage
Proportional Hazards Models
Sexual Behavior/psychology
Sexual Partners/psychology
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:44RAL3456C (Methamphetamine)
[Em] Entry month:1801
[Cu] Class update date: 180123
[Lr] Last revision date:180123
[Js] Journal subset:IM
[Da] Date of entry for processing:170428
[St] Status:MEDLINE

  4 / 2613 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
SciELO Brazil full text

[PMID]: 28700012
[Au] Autor:Massaro LTS; Abdalla RR; Laranjeira R; Caetano R; Pinsky I; Madruga CS
[Ad] Address:Instituto Nacional de Cincia e Tecnologia para Polticas Pblicas do lcool e Outras Drogas (INPAD), So Paulo, SP, Brazil.
[Ti] Title:Amphetamine-type stimulant use and conditional paths of consumption: data from the Second Brazilian National Alcohol and Drugs Survey.
[So] Source:Rev Bras Psiquiatr;39(3):201-207, 2017 Jul-Sep.
[Is] ISSN:1809-452X
[Cp] Country of publication:Brazil
[La] Language:eng
[Ab] Abstract:Objective:: The aim of this study was to estimate nationally representative prevalence rates of amphetamine-type stimulant (ATS) use and to identify consumption-associated factors, proposing a conditional model of direct and indirect consumption paths. Method:: Using data from the Second Brazilian National Alcohol and Drugs Survey, this cross-sectional study analyzed a subsample of 3,828 participants between 15 and 64 years old, gathering information on the use of psychoactive substances in a probabilistic sample of the Brazilian household population. Results:: Rates of lifetime and last-year ATS use were, respectively, 4.1 and 1.6%. Economically privileged individuals and users of other substances were more at risk for using ATS. The results suggest that higher education decreases the chances of ATS consumption. The conditional model showed that higher income increased ATS use, higher education lowered the odds of such an increase, and cocaine use cancelled that associative effect. Conclusion:: Brazil presents high rates of ATS use. Prevention and treatment strategies should focus on the protective effect of higher education levels and should target polydrug use. Knowledge of ATS-associated factors and user profiles is the starting point for developing effective treatments and tailored prevention strategies.
[Mh] MeSH terms primary: Amphetamine-Related Disorders/epidemiology
Surveys and Questionnaires
[Mh] MeSH terms secundary: Adolescent
Adult
Brazil/epidemiology
Cocaine-Related Disorders/epidemiology
Cross-Sectional Studies
Educational Status
Female
Humans
Income/statistics & numerical data
Male
Middle Aged
Prevalence
Sex Distribution
Young Adult
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171106
[Lr] Last revision date:171106
[Js] Journal subset:IM
[Da] Date of entry for processing:170713
[St] Status:MEDLINE

  5 / 2613 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28630283
[Au] Autor:Moszczynska A; Callan SP
[Ad] Address:Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan amosz@wayne.edu.
[Ti] Title:Molecular, Behavioral, and Physiological Consequences of Methamphetamine Neurotoxicity: Implications for Treatment.
[So] Source:J Pharmacol Exp Ther;362(3):474-488, 2017 Sep.
[Is] ISSN:1521-0103
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Understanding the relationship between the molecular mechanisms underlying neurotoxicity of high-dose methamphetamine (METH) and related clinical manifestations is imperative for providing more effective treatments for human METH users. This article provides an overview of clinical manifestations of METH neurotoxicity to the central nervous system and neurobiology underlying the consequences of administration of neurotoxic METH doses, and discusses implications of METH neurotoxicity for treatment of human abusers of the drug.
[Mh] MeSH terms primary: Methamphetamine/toxicity
Neurotoxicity Syndromes/complications
[Mh] MeSH terms secundary: Amphetamine-Related Disorders/drug therapy
Animals
Cognitive Dysfunction/chemically induced
Cognitive Dysfunction/drug therapy
Dopaminergic Neurons/drug effects
Dose-Response Relationship, Drug
Humans
Methamphetamine/pharmacology
Neural Pathways/drug effects
Neurotoxicity Syndromes/drug therapy
Serotonergic Neurons/drug effects
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:44RAL3456C (Methamphetamine)
[Em] Entry month:1708
[Cu] Class update date: 170829
[Lr] Last revision date:170829
[Js] Journal subset:IM
[Da] Date of entry for processing:170621
[St] Status:MEDLINE
[do] DOI:10.1124/jpet.116.238501

  6 / 2613 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28434182
[Au] Autor:Wilkins C; Prasad J; Parker K; Rychert M; Barnes HM
[Ad] Address:SHORE and Whariki Research Centre, College of Health, Massey University, Auckland, New Zealand. C.Wilkins@massey.ac.nz.
[Ti] Title:Recent Trends in Alcohol and Other Drug Use Among Police Detainees in New Zealand, 2010-2015.
[So] Source:Curr Top Behav Neurosci;34:161-172, 2017.
[Is] ISSN:1866-3370
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:BACKGROUND: New Zealand has unusual patterns of recreational substance use by international standards including low levels of cocaine and heroin use, and high methamphetamine use. AIMS: This paper examines recent trends in alcohol and other drug use among police detainees in New Zealand over the past six years. METHOD: The paper utilises data from the New Zealand Arrestee Drug Use Monitoring (NZ-ADUM) study. NZ-ADUM interviewed approximately 800 police detainees each year at four central city police watch houses (i.e. Whangarei, Auckland, Wellington, Christchurch) from 2010 to 2015. RESULTS: The proportion of police detainees who had used methamphetamine in the previous year increased from 28% in 2012 to 36% in 2015. Drinking prior to arrest declined from 41% in 2013 to 28% in 2015. The use of cannabis in the past year declined slightly from 76% in 2011 to 69% in 2015. The proportion using ecstasy in the previous year steadily declined from 28% in 2011 to 19% in 2015. Only small minorities had recently used cocaine or an opioid. Use of methamphetamine and ecstasy increased in Christchurch. CONCLUSION: Growing methamphetamine use is consistent with record seizures of methamphetamine over the past 2-3years. Increasing drug use in Christchurch may reflect factors related to the devastating earthquakes in 2011 and the subsequent city rebuild, including an influx of construction workers, more organised trafficking groups and earthquake-related stress. The decline in cannabis use may be related to the emergence of 'legal' synthetic cannabinoids. The decline in ecstasy use may be the result of recent domestic enforcement operations and the overall global shortage of MDMA. The decline in alcohol drinking may be due to the introduction of pre-charge formal warnings for minor alcohol and disorder offences, and new restrictions on alcohol premise opening hours. Acknowledgements: The New Zealand Drug Use Monitoring (NZ-ADUM) research study is funded by the New Zealand Police and is conducted by SHORE and Whariki Research Centre, College of Health at Massey University, Auckland. We would like to thank New Zealand Police staff at Whangarei, Auckland Central, Wellington Central and Christchurch Central police watch houses for their assistance and cooperation with this research. We would also like to thank all the interviewers who worked with us on NZ-ADUM and all the police detainees who agreed to be interviewed for the study. The views expressed in this paper are entirely our own and do not necessarily reflect those of New Zealand Police.
[Mh] MeSH terms primary: Alcoholism/epidemiology
Amphetamine-Related Disorders/epidemiology
Cocaine-Related Disorders/epidemiology
Marijuana Smoking/epidemiology
Opioid-Related Disorders/epidemiology
Prisoners/statistics & numerical data
[Mh] MeSH terms secundary: Adult
Analgesics, Opioid
Cannabis
Cocaine
Female
Humans
Male
Methamphetamine
N-Methyl-3,4-methylenedioxyamphetamine
New Zealand/epidemiology
Substance-Related Disorders/epidemiology
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Analgesics, Opioid); 44RAL3456C (Methamphetamine); I5Y540LHVR (Cocaine); KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
[Em] Entry month:1710
[Cu] Class update date: 171017
[Lr] Last revision date:171017
[Js] Journal subset:IM
[Da] Date of entry for processing:170424
[St] Status:MEDLINE
[do] DOI:10.1007/7854_2016_471

  7 / 2613 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28422859
[Au] Autor:Zhang M; Lv D; Zhou W; Ji L; Zhou B; Chen H; Gu Y; Zhao J; He J
[Ad] Address:aDepartment of Clinical Laboratory bDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
[Ti] Title:The levels of triglyceride and total cholesterol in methamphetamine dependence.
[So] Source:Medicine (Baltimore);96(16):e6631, 2017 Apr.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The serum triglyceride (TG) and total cholesterol (TC) levels have been reported altered in the traditional drug-dependence (such as marijuana and heroin). However, studies assessing the relationships among serum TC, TG, and methamphetamine (MA)-dependence have not been described well. In this study, our aim is to explore the serum TG and TC levels in large sample of MA-dependent patients. A retrospective study was conducted in 938 MA-dependent patients who were recruited between February 2, 2008 and March 11, 2013, with social characteristics and drug-dependence history (duration of MA use, routes of drug administration, and daily dose were collected). Then, the serum levels of TC, TG, glucose (GLU), body mass index (BMI), and blood pressure were measured among the participants. Meanwhile, 985 age- and gender-matched healthy people in the physical examination center were selected as control group. Compared with the control group, significant decreases of TC, TG, GLU, and BMI were observed in MA-dependent patients (P < 0.05). Besides, we found that the daily dose of MA use was associated with TC ( = -0.079, P = 0.015) and the duration of MA use was independently related to BMI ( = -0.071, P = 0.031). This study demonstrated that the levels of TC, TG, GLU, and BMI factors altered in the MA-dependent patients. In addition, there is a negative association between MA dependence and TC and BMI.
[Mh] MeSH terms primary: Amphetamine-Related Disorders/blood
Cholesterol/blood
Triglycerides/blood
[Mh] MeSH terms secundary: Adolescent
Adult
Blood Glucose
Blood Pressure
Body Mass Index
Female
Humans
Male
Middle Aged
Retrospective Studies
Socioeconomic Factors
Young Adult
[Pt] Publication type:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Name of substance:0 (Blood Glucose); 0 (Triglycerides); 97C5T2UQ7J (Cholesterol)
[Em] Entry month:1705
[Cu] Class update date: 170509
[Lr] Last revision date:170509
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:170420
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000006631

  8 / 2613 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28403074
[Au] Autor:Su H; Zhang J; Ren W; Xie Y; Tao J; Zhang X; He J
[Ad] Address:aDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou bShanghai Mental Health Center, Shanghai Jiaotong University School of Medicine cDepartment of Neurology, Zhongshan Hospital, Fudan University, Shanghai dDepartment of Neurology, The First Affiliated Hospital of Yangtze University, Jingzhou eSir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou fBeijing HuiLongGuan Hospital, Peking University, Beijing, China gDepartment of Psychiatry and Behavioral Sciences, Harris County Psychiatric Center, The University of Texas Health Science Center at Houston, Houston, TX.
[Ti] Title:Anxiety level and correlates in methamphetamine-dependent patients during acute withdrawal.
[So] Source:Medicine (Baltimore);96(15):e6434, 2017 Apr.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Anxiety is often a core element of withdrawal symptoms; however, risk factors associated with anxiety symptoms during the early stage of withdrawal in methamphetamine (METH) users are not well understood. Two hundred ten METH-dependent subjects who had been abstinent for 1 to 7 days were recruited. We used a set of self-administrative questionnaires eliciting information on sociodemographics, detailed drug use history and anxiety. Beck Anxiety Inventory (BAI) was used to measure anxiety symptoms. METH users had a mean BAI score of 6.9; 72 (34.3%) of the study sample had anxiety symptoms during acute METH withdrawal, including 42 (20.0%) with mild anxiety, 25 (11.9%) with moderate anxiety, and 5 (2.4%) with severe anxiety. In addition, gender (female), higher frequency of drug use, and history of polysubstance use were significantly correlated with anxiety symptoms during acute METH withdrawal. Anxiety symptoms appear to be common during the first week of METH abstinence, and several risk factors are identified.
[Mh] MeSH terms primary: Amphetamine-Related Disorders/psychology
Anxiety/chemically induced
Central Nervous System Stimulants/adverse effects
Methamphetamine/adverse effects
Substance Withdrawal Syndrome/psychology
[Mh] MeSH terms secundary: Adolescent
Adult
Female
Humans
Male
Middle Aged
Psychiatric Status Rating Scales
Risk Factors
Sex Factors
Surveys and Questionnaires
Time Factors
Young Adult
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Central Nervous System Stimulants); 44RAL3456C (Methamphetamine)
[Em] Entry month:1704
[Cu] Class update date: 170430
[Lr] Last revision date:170430
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:170414
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000006434

  9 / 2613 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28351169
[Au] Autor:Morley KC; Cornish JL; Faingold A; Wood K; Haber PS
[Ad] Address:a NHMRC Centre for Excellence in Mental Health and Substance Use, Discipline of Addiction Medicine , The University of Sydney , Sydney , Australia.
[Ti] Title:Pharmacotherapeutic agents in the treatment of methamphetamine dependence.
[So] Source:Expert Opin Investig Drugs;26(5):563-578, 2017 May.
[Is] ISSN:1744-7658
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:INTRODUCTION: Methamphetamine use is a serious public health concern in many countries and is second to cannabis as the most widely abused illicit drug in the world. Effective management for methamphetamine dependence remains elusive and the large majority of methamphetamine users relapse following treatment. Areas covered: Progression in the understanding of the pharmacological basis of methamphetamine use has provided us with innovative opportunities to develop agents to treat dependence. The current review summarizes relevant literature on the neurobiological and clinical correlates associated with methamphetamine use. We then outline agents that have been explored for potential treatments in preclinical studies, human laboratory phase I and phase II trials over the last ten years. Expert opinion: No agent has demonstrated a broad and strong effect in achieving MA abstinence in Phase II trials. Agents with novel therapeutic targets appear promising. Advancement in MA treatment, including translation into practice, faces several clinical challenges.
[Mh] MeSH terms primary: Amphetamine-Related Disorders/drug therapy
Drug Design
Methamphetamine/adverse effects
[Mh] MeSH terms secundary: Amphetamine-Related Disorders/epidemiology
Animals
Central Nervous System Stimulants/administration & dosage
Central Nervous System Stimulants/adverse effects
Humans
Methamphetamine/administration & dosage
Molecular Targeted Therapy
Recurrence
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Central Nervous System Stimulants); 44RAL3456C (Methamphetamine)
[Em] Entry month:1706
[Cu] Class update date: 170605
[Lr] Last revision date:170605
[Js] Journal subset:IM
[Da] Date of entry for processing:170330
[St] Status:MEDLINE
[do] DOI:10.1080/13543784.2017.1313229

  10 / 2613 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 28319198
[Au] Autor:Uno K; Miyazaki T; Sodeyama K; Miyamoto Y; Nitta A
[Ad] Address:Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
[Ti] Title:Methamphetamine induces Shati/Nat8L expression in the mouse nucleus accumbens via CREB- and dopamine D1 receptor-dependent mechanism.
[So] Source:PLoS One;12(3):e0174196, 2017.
[Is] ISSN:1932-6203
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Shati/Nat8L significantly increased in the nucleus accumbens (NAc) of mice after repeated methamphetamine (METH) treatment. We reported that Shati/Nat8L overexpression in mouse NAc attenuated METH-induced hyperlocomotion, locomotor sensitization, and conditioned place preference. We recently found that Shati/Nat8L overexpression in NAc regulates the dopaminergic neuronal system via the activation of group II mGluRs by elevated N-acetylaspartylglutamate following N-acetylaspartate increase due to the overexpression. These findings suggest that Shati/Nat8L suppresses METH-induced responses. However, the mechanism by which METH increases the Shati/Nat8L mRNA expression in NAc is unclear. To investigate the regulatory mechanism of Shati/Nat8L mRNA expression, we performed a mouse Shati/Nat8L luciferase assay using PC12 cells. Next, we investigated the response of METH to Shati/Nat8L expression and CREB activity using mouse brain slices of NAc, METH administration to mice, and western blotting for CREB activity of specific dopamine receptor signals in vivo and ex vivo. We found that METH activates CREB binding to the Shati/Nat8L promoter to induce the Shati/Nat8L mRNA expression. Furthermore, the dopamine D1 receptor antagonist SCH23390, but not the dopamine D2 receptor antagonist sulpiride, inhibited the upregulation of Shati/Nat8L and CREB activities in the mouse NAc slices. Thus, the administration of the dopamine D1 receptor agonist SKF38393 increased the Shati/Nat8L mRNA expression in mouse NAc. These results showed that the Shati/Nat8L mRNA was increased by METH-induced CREB pathway via dopamine D1 receptor signaling in mouse NAc. These findings may contribute to development of a clinical tool for METH addiction.
[Mh] MeSH terms primary: Acetyltransferases/metabolism
Central Nervous System Stimulants/pharmacology
Cyclic AMP Response Element-Binding Protein/metabolism
Methamphetamine/pharmacology
Nucleus Accumbens/drug effects
Receptors, Dopamine D1/metabolism
[Mh] MeSH terms secundary: Acetyltransferases/genetics
Amphetamine-Related Disorders/metabolism
Animals
Conditioning (Psychology)/drug effects
Conditioning (Psychology)/physiology
Dopamine Agents/pharmacology
Gene Expression/drug effects
Male
Mice, Inbred C57BL
Motor Activity/drug effects
Motor Activity/physiology
Nucleus Accumbens/metabolism
PC12 Cells
Promoter Regions, Genetic
RNA, Messenger/metabolism
Rats
Receptors, Dopamine D2/metabolism
Spatial Behavior/drug effects
Spatial Behavior/physiology
Tissue Culture Techniques
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Central Nervous System Stimulants); 0 (Creb1 protein, mouse); 0 (Cyclic AMP Response Element-Binding Protein); 0 (DRD2 protein, mouse); 0 (Dopamine Agents); 0 (RNA, Messenger); 0 (Receptors, Dopamine D1); 0 (Receptors, Dopamine D2); 44RAL3456C (Methamphetamine); EC 2.3.1.- (Acetyltransferases); EC 2.3.1.- (Shati protein, mouse)
[Em] Entry month:1708
[Cu] Class update date: 170829
[Lr] Last revision date:170829
[Js] Journal subset:IM
[Da] Date of entry for processing:170321
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0174196


page 1 of 262 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information